Neuronostics Raises £3M to Fast-Track Digital Biomarker Platform for Epilepsy Diagnosis

Bristol Startup Secures £3M to Transform Digital Biomarker Epilepsy Diagnosis

Bristol-based health tech startup Neuronostics has secured £3 million in funding to accelerate the development of BioEP, its patented digital biomarker platform designed to improve epilepsy diagnosis and prognosis. The raise highlights a growing investor appetite for AI-powered medical diagnostics tools that address long-standing clinical bottlenecks — and for a condition affecting roughly 50 million people worldwide, the stakes could hardly be higher.

Epilepsy remains one of the most diagnostically challenging neurological conditions in modern medicine. According to figures cited by Neuronostics, people with suspected epilepsy routinely wait over a year for a confirmed diagnosis. Misdiagnosis rates can exceed 30%, and around half of patients are not seizure-free one year after beginning treatment. These are not just clinical failures — they are systemic data problems, and the BioEP platform is being built to address them at a technical level.

The core technology centres on the electroencephalogram (EEG), a test that measures electrical activity in the brain. While EEGs have been a clinical staple for decades, their diagnostic value has historically been constrained by the time and specialist expertise required to interpret results. Neuronostics is applying computational methods and machine learning to extract consistent, reproducible biomarkers from EEG data — turning a labour-intensive clinical process into a scalable, data-driven one.

Why Epilepsy Diagnosis Has Been a Data Problem All Along

For developers, privacy professionals, and IT decision-makers working in or adjacent to health tech, the Neuronostics story is instructive precisely because epilepsy diagnosis is, at its core, an information problem. EEG signals are rich in data, but extracting actionable insight from them demands both clinical expertise and computational power that most health systems cannot reliably supply at scale.

The World Health Organization estimates that epilepsy affects approximately 50 million people globally, making it one of the most common neurological diseases worldwide. Yet access to neurological specialists capable of interpreting EEG data remains deeply uneven — both between countries and within them. Research published in The Lancet Neurology has repeatedly highlighted the diagnostic treatment gap, particularly in lower-resource health systems, but even well-funded European healthcare infrastructures struggle with neurologist shortages and diagnostic backlogs.

This is where digital biomarker platforms represent a structural shift. Rather than replacing clinicians, tools like BioEP are designed to surface objective, reproducible signals from EEG recordings that clinicians can then act on faster and with greater confidence. The platform essentially compresses the analytical work that would otherwise require hours of specialist review into a format that supports decision-making at speed.

How BioEP Works — and What It Means for Clinical Data Infrastructure

BioEP is a patented platform, which signals that the underlying computational methodology has been assessed for novelty and defensibility. While the full technical architecture has not been disclosed publicly, digital biomarker platforms of this type typically combine signal processing algorithms with machine learning models trained on large annotated datasets of EEG recordings. The output is a structured biomarker — a quantified, reproducible measure that can be integrated into clinical workflows.

For IT decision-makers and technical architects working in health systems, the infrastructure implications are significant. Platforms that process EEG data at scale must navigate complex requirements around data storage, interoperability (particularly HL7 FHIR standards), and — critically in the European context — GDPR compliance. Neurological data is classified as sensitive health data under GDPR Article 9, meaning that any platform processing it must implement appropriate technical and organisational safeguards, data minimisation practices, and lawful processing bases.

This is not a peripheral concern. According to analysis from the European Health Data Space initiative, one of the primary barriers to scaling AI-powered diagnostics across EU member states is the fragmentation of health data governance frameworks. A platform like BioEP that is designed for clinical deployment will need to demonstrate not only diagnostic efficacy but also compliance with the evolving EU AI Act's requirements for high-risk AI systems — which explicitly includes AI used in medical diagnosis.

For entrepreneurs and small business owners building adjacent tools — whether that is data pipeline infrastructure, clinical-grade anonymisation services, or FHIR-compliant API layers — the growth of platforms like BioEP represents a concrete market pull. The health tech sector increasingly needs partners who can handle the data sovereignty and privacy architecture that underpins regulatory compliance.

Where Neuronostics Fits in the Broader European Neurotech Landscape

The UK's health tech ecosystem has positioned itself as a serious contender in computational neuroscience and digital diagnostics, with Bristol, London, and Edinburgh each hosting clusters of neurotech activity. Neuronostics is among a cohort of startups leveraging NHS data access and academic partnerships to build tools that are both clinically grounded and commercially viable.

Across Europe, the neurotech investment landscape has been maturing steadily. According to data tracked by Crunchbase, European neurotech and digital health startups have attracted increasing venture capital interest over recent years, with particular momentum in AI-assisted diagnostics and remote monitoring tools. This is partly driven by post-pandemic pressure on health systems to find scalable alternatives to in-person specialist consultations.

The regulatory environment is also evolving rapidly in ways that will shape how platforms like BioEP are deployed. The EU AI Act, which came into force in 2024, classifies AI systems used in medical diagnosis as high-risk, requiring conformity assessments, transparency obligations, and human oversight mechanisms. For policy professionals tracking AI regulation, Neuronostics' trajectory will be a useful case study in how a UK-based startup navigates both UKCA marking (the UK's post-Brexit equivalent of CE marking) and potential EU market access requirements.

Health Data, Digital Sovereignty, and the Privacy Architecture Behind AI Diagnostics

For privacy professionals and those working on data sovereignty frameworks, AI diagnostic platforms represent one of the most complex deployment environments in existence. Neurological data — EEG recordings, seizure histories, brain activity patterns — is among the most sensitive categories of personal data recognised under GDPR. Any platform processing this data, particularly one using machine learning models trained on population-level datasets, must address questions that go well beyond basic consent.

Key technical considerations include: where data is stored and processed (cloud region, data residency requirements), how training data was sourced and whether it was appropriately anonymised, how model outputs are explained to clinicians (explainability requirements under the EU AI Act), and how audit trails are maintained for regulatory review. These are not abstract concerns — they directly determine whether a platform like BioEP can achieve clinical certification and NHS or EU health system procurement.

Research from the Nature Medicine journal on AI in clinical settings has highlighted that model performance on training datasets frequently fails to generalise across different health system contexts, partly because data collection protocols, EEG equipment calibration, and patient demographics vary significantly. This is a known challenge in deploying AI diagnostic tools at scale, and it points to the need for federated learning approaches or robust cross-site validation protocols — both of which have significant implications for data architecture and privacy engineering.

From a digital sovereignty perspective, the provenance of health data used to train diagnostic AI models is increasingly a policy concern in Europe. The European Health Data Space is specifically designed to create a governed framework for cross-border health data sharing that preserves member state sovereignty

Originally reported by UKTN. Summarised and curated by European Purpose.